PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Clinical Trials
5.0k
Trial Phases
6 Phases
Drug Approvals
69
Drug Approvals
Rimegepant Sulfate Orally Disintegrating Tablets
- Product Name
- 乐泰可
- Approval Number
- 国药准字HJ20240004
- Approval Date
- Jan 23, 2024
Ritlecitinib Tosylate Capsules
- Product Name
- 乐复诺
- Approval Number
- 国药准字HJ20230118
- Approval Date
- Oct 18, 2023
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (3901 trials with phase data)• Click on a phase to view related trials
A Study to Learn About the Study Medicine Called PF-07258669 in Older Adults Including Those at Risk of Malnutrition
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-07-25
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT07086664
- Locations
- 🇺🇸
Javara - Nevada Health Centers - Carson City, Carson City, Nevada, United States
A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)
- Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC)Cancer of the ProstateProstate NeoplasmsProstate Cancer
- Interventions
- First Posted Date
- 2025-07-25
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1300
- Registration Number
- NCT07086651
A Study to Learn About How a New Pneumococcal Vaccine Works in Adults
- Conditions
- Streptococcus Pneumoniae
- Interventions
- Biological: PG4 vaccine in Buffer 1 with low dose PA-001Biological: PG4 in Buffer 1 with low dose PA-002Biological: PG4 in Buffer 1 with high dose PA-001Biological: PG4 vaccine in Buffer 1 with high dose PA-002Biological: PG4 vaccine in Buffer 2Biological: Saline injection
- First Posted Date
- 2025-07-25
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 372
- Registration Number
- NCT07086677
- Locations
- 🇺🇸
Orange County Research Center, Lake Forest, California, United States
🇺🇸Indago Research & Health Center, Inc, Hialeah, Florida, United States
🇺🇸Johnson County Clinical Trials, Lenexa, Kansas, United States
A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
- First Posted Date
- 2025-07-18
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT07073820
A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe
- Conditions
- COVID-19 (Coronavirus Disease 2019)
- Interventions
- Drug: nirmatrelvir-ritonavir
- First Posted Date
- 2025-07-18
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 84584
- Registration Number
- NCT07072793
- Locations
- 🇺🇸
Pfizer New York, New York, New York, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 636
- Next
News
Comprehensive Pipeline Analysis Reveals 200+ Investigational Drugs for Metastatic Hormone Refractory Prostate Cancer
A new comprehensive report analyzes over 200 pipeline drugs from 180+ companies targeting metastatic hormone refractory prostate cancer, highlighting the extensive research efforts in this challenging therapeutic area.
Bristol Myers Squibb Appoints AstraZeneca's Cristian Massacesi as New Chief Medical Officer
Bristol Myers Squibb has appointed Cristian Massacesi, M.D., former AstraZeneca Chief Medical Officer, as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025.
EU Regulatory Approval Advances Pfizer-BioNTech LP.8.1-Adapted COVID-19 Vaccine for 2025-2026 Season
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Pfizer and BioNTech's LP.8.1-adapted COMIRNATY vaccine targeting XFG and NB.1.8.1 variants.
Roche Explores Direct-to-Consumer Drug Sales Model to Reduce US Patient Costs
Roche is considering selling prescription medicines directly to US consumers to lower patient costs, following government pressure to reduce drug prices.
RedHill Biopharma Receives FDA Approval for Groundbreaking MAP-Targeted Crohn's Disease Study
RedHill Biopharma received positive FDA feedback for the first-ever clinical study targeting Mycobacterium avium subspecies paratuberculosis (MAP) infected Crohn's disease patients with RHB-204.
Turkish Study Links Pfizer COVID-19 Vaccine to Corneal Structural Changes
A Turkish study of 64 patients found measurable corneal changes 75 days after receiving two doses of the Pfizer-BioNTech COVID-19 vaccine, including 2% increased thickness and 8% reduced endothelial cell density.
BioNTech Chief Strategy Officer Ryan Richardson to Step Down After Seven-Year Tenure
Ryan Richardson will step down as Chief Strategy Officer from BioNTech's Management Board on September 30, 2025, after serving since January 2020.
Bristol Myers Squibb and Pfizer Launch Direct-to-Patient Eliquis Program with 40% Price Discount
Bristol Myers Squibb and Pfizer announced a new direct-to-patient purchasing option for Eliquis (apixaban) through their Eliquis 360 Support program, offering eligible patients a cash price more than 40% below the current $606 list price.
Sarepta Therapeutics Implements $400 Million Cost-Cutting Plan Amid Regulatory Challenges for Gene Therapy
Sarepta Therapeutics announced a $400 million annual cost-savings initiative in July 2025, including a 36% workforce reduction of 500 employees to achieve financial sustainability through 2027.
Iovance Biotherapeutics Names Corleen Roche as CFO During Commercial Launch of First FDA-Approved TIL Therapy
Iovance Biotherapeutics appointed Corleen Roche as Chief Financial Officer effective August 6, 2025, during the commercial launch of its groundbreaking TIL therapy.